BAMF Health
Grand Rapids, Michigan 49503
9 studies enrolling now · 19 studies all time
What they study most
B7H3, Brain Metastases From Solid Tumors, Bronchial Neuroendocrine Tumor, Castration Resistant Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Cervical Adenocarcinoma, Cervical Cancer, Cholangiocarcinoma, Colorectal Adenocarcinoma, Colorectal Cancer, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Studies at this site
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers — Recruiting now
- A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors — Recruiting now
- Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) — Recruiting now
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors — Recruiting now
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy — Recruiting now
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) — Recruiting now
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors — Recruiting now
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT — Running, not enrolling
- Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma — Completed
- Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases — Running, not enrolling
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Running, not enrolling
- Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) — Running, not enrolling
- Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers — Completed
- Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer — Completed
- PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer — Running, not enrolling
- Total Body PET-CT Imaging of Prostate Cancer Using Illuccix — Status unconfirmed
- Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) — Status unconfirmed